The category A intracellular bacterial pathogen Francisella tularensis, the category B bacterium Listeria monocytogenes, Mycobacterium tuberculosis, and numerous other important human intracellular pathogens have evolved to benefit from stimulating the host to produce type I interferons (IFN??). Our prior studies with L. monocytogenes revealed a mechanism by which IFN?? can increase host susceptibility to these infections. We found that IFN?? suppresses the activation of macrophages by causing rapid reductions in myeloid cell expression of the receptor for type II IFN, IFN?. In the R21 phase of this R21/R33 proposal, we will use novel reagents and tools developed in our lab to experimentally test whether host-targeted interventions that prevent down regulation of myeloid cell IFNGR by IFN?? have therapeutic effects in the context of mucosal and systemic bacterial infections.
In Aim 1, we will investigate whether transgenic mice developed in our laboratory that do not down regulate IFNGR in myeloid cells have increased resistance to systemic and mucosal bacterial infection.
In Aim 2, we use inhibitors of a host kinase that plays a role in IFNGR down regulation to test for potential pre- and post-exposure therapy. In the R33 phase, we outline our strategy to screen for additional small molecule inhibitors of IFNGR down regulation. We will also characterize the effects of the SM inhibitors and identify their host targets.
Aim 3 outlines our screening approach and secondary screens we will use to identify selective small molecule inhibitors of IFNGR down regulation.
In Aim 4, we will define the global effects of these inhibitors on constitutive and IFN??-regulated macrophage gene expression and use SM inhibitors to identify novel host proteins that contribute to IFNGR down regulation by IFN?? and thus may be targets for host-directed interventions to treat infectious diseases.
When appropriately activated, macrophages and other myeloid cells can efficiently engulf and kill bacteria. However, host factors that suppress this activation facilitate more severe bacterial infections. Our studies will investigate host-targeted interventions that prevent host suppression of myeloid cell activation and may thus improve resistance to bacterial infections.
| Crisler, William J; Lenz, Laurel L (2018) Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection. Curr Opin Immunol 54:35-41 |
| Eshleman, Emily M; Delgado, Christine; Kearney, Staci J et al. (2017) Down regulation of macrophage IFNGR1 exacerbates systemic L. monocytogenes infection. PLoS Pathog 13:e1006388 |
| Mills, Charles D; Lenz, Laurel L; Harris, Robert A (2016) A Breakthrough: Macrophage-Directed Cancer Immunotherapy. Cancer Res 76:513-6 |
| Mills, Charles D; Lenz, Laurel L; Ley, Klaus (2015) Macrophages at the fork in the road to health or disease. Front Immunol 6:59 |
| Mills, Charles D; Thomas, Anita C; Lenz, Laurel L et al. (2014) Macrophage: SHIP of Immunity. Front Immunol 5:620 |
| Kedl, Ross M; Wysocki, Lawrence J; Janssen, William J et al. (2014) General parity between trio and pairwise breeding of laboratory mice in static caging. J Immunol 193:4757-60 |
| Eshleman, Emily M; Lenz, Laurel L (2014) Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Front Immunol 5:431 |
